Cargando…

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer

In patients with castration-resistant prostate cancer (CRPC), clinical resistances such as androgen receptor (AR) mutation, AR overexpression, and AR splice variants (ARVs) limit the effectiveness of second-generation antiandrogens (SGAs). Several strategies have been implemented to develop novel an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Meng, Zhang, Rongyu, Zhang, Zixiong, Zhang, Ning, Li, Chenfan, Xie, Yongli, Xia, Haoran, Huang, Fangjiao, Zhang, Ruoying, Liu, Ming, Li, Xiaoyu, Cen, Shan, Zhou, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2023
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901937/ https://www.ncbi.nlm.nih.gov/pubmed/36656639 http://dx.doi.org/10.7554/eLife.70700

Ejemplares similares

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance
por: Lee, Eugine, et al.
Publicado: (2019)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
por: Congregado Ruiz, Belén, et al.
Publicado: (2023)

Overcoming mutation-based resistance to antiandrogens with rational drug design
por: Balbas, Minna D, et al.
Publicado: (2013)

Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site
por: Liu, Yangguang, et al.
Publicado: (2018)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
por: Anker, Jonathan F., et al.
Publicado: (2018)

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
por: Shah, Neel, et al.
Publicado: (2017)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice
por: Huhtaniemi, Riikka, et al.
Publicado: (2022)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens()()
por: Nunes, Jessica J., et al.
Publicado: (2017)

Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
por: Tian, Xiaohong, et al.
Publicado: (2015)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment
por: Cheng, Bisheng, et al.
Publicado: (2023)

Corrigendum: Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
por: Tian, Xiaohong, et al.
Publicado: (2015)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Exosomal TUBB3 mRNA expression of metastatic castration‐resistant prostate cancer patients: Association with patient outcome under abiraterone
por: Zhu, Sha, et al.
Publicado: (2021)

Designer antiandrogens join the race against drug resistance
por: Josan, Jatinder S, et al.
Publicado: (2013)

Reversing resistance to antiandrogens with a histone deacetylase inhibitor
por: Ferrari, Anna C.
Publicado: (2018)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
por: Maitland, Norman J.
Publicado: (2021)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Caractéristiques démographiques de la race ovine sarde
por: Lauvergne, J-J, et al.
Publicado: (1973)

Androgen deprivation-induced OPHN1 amplification promotes castration-resistant prostate cancer
por: Liu, Junjiang, et al.
Publicado: (2022)

Influence of statins in metastatic castration-resistant prostate cancer patients treated with new antiandrogen therapies: a systematic review and meta-analysis
por: Mariano, Renato, et al.
Publicado: (2022)

Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor‐κB signaling in esophageal squamous cell carcinoma
por: Wu, Junzhou, et al.
Publicado: (2017)

GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo
por: Jiang, Kaili, et al.
Publicado: (2021)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2021)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0igcvmu8bab5f6vtmr4vh1d9b3